Skip to main content
  • Register
  • Help
  • Contact us
  • Log out of your HL account

Novavax Inc (NVAX) USD0.01

Sell:$15.05 Buy:$15.60 Change: $1.75 (12.63%)
NASDAQ:1.53%
Market closed |  Prices as at close on 3 April 2020 | Switch to live prices |
Sell:$15.05
Buy:$15.60
Change: $1.75 (12.63%)
Market closed |  Prices as at close on 3 April 2020 | Switch to live prices |
Sell:$15.05
Buy:$15.60
Change: $1.75 (12.63%)
Market closed |  Prices as at close on 3 April 2020 | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Novavax, Inc. is a clinical-stage vaccine company focused on the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants. The Company operates through developing recombinant vaccines segment. The Company, through its recombinant nanoparticle vaccine technology, produces vaccine candidates to respond to both known and newly emerging diseases. The Company's product pipeline focuses on a range of infectious diseases with vaccine candidates in clinical development for respiratory syncytial virus (RSV), seasonal influenza, pandemic influenza and the Ebola virus (EBOV). The Company's lead adjuvant for human applications, Matrix-M, is in a Phase I/II clinical trial for pandemic influenza H7N9 vaccine candidate. It is also testing Matrix-M in conjunction with its EBOV vaccine candidate in a Phase I clinical trial. It is developing additional pre-clinical stage programs in a range of infectious diseases, including Middle East respiratory syndrome (MERS).

Contact details

Address:
21 Firstfield Rd
GAITHERSBURG
20878-1757
United States
Telephone:
+1 (240) 2682000
Website:
www.novavax.com/

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
NVAX
ISIN:
US6700024010
Market cap:
$714.19 million
Shares in issue:
51.53 million
Sector:
Biotechnology
Exchange:
NASDAQ
Country:
United States
Currency:
US dollar
Indices:
NASDAQ Comb. Composite

Key personnel

  • James Young
    Independent Chairman of the Board
  • Stanley Erck
    President, Chief Executive Officer, Director
  • John Trizzino
    Senior Vice President, Chief Business Officer, Chief Financial Officer and Treasurer
  • Gregory Glenn
    President, Research and Development
  • John Herrmann
    Senior Vice President, General Counsel, Corporate Secretary
  • Jody Lichaa
    Senior Vice President - Quality Assurance
  • Brian Rosen
    Senior Vice President - Commercial Strategy

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.

Share

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.